NVCR NovoCure Ltd

Price (delayed)

$14.13

Market cap

$1.64B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.53

Enterprise value

$1.77B

?
Relative Growth: Rel. Growth: 29
Relative Strength: Rel. Strength: 50
Relative Valuation: Rel. Valuation: 20
Relative Profitability: Rel. Profitability: 30

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating ...

Highlights
The company's quick ratio has surged by 91% YoY
NovoCure's debt has plunged by 66% YoY
The net income has contracted by 27% from the previous quarter and by 5% YoY
NVCR's EPS is down by 25% since the previous quarter

Key stats

What are the main financial stats of NVCR

NVCR stock price

How has the NovoCure stock price performed over time
Intraday
3.82%
1 week
-19.21%
1 month
-21.33%
1 year
-14.93%
YTD
9.28%
QTD
29.63%

Financial performance

How have NovoCure's revenue and profit performed over time
Revenue
$674.41M
Gross profit
$507.13M
Operating income
-$183.36M
Net income
-$173.05M
Gross margin
75.2%
Net margin
-25.7%
The net income has contracted by 27% from the previous quarter and by 5% YoY
NovoCure's net margin has decreased by 24% from the previous quarter but it has increased by 2.7% YoY
NovoCure's operating income has decreased by 19% QoQ and by 10% YoY
NovoCure's operating margin has decreased by 16% QoQ

Price vs fundamentals

How does NVCR's price correlate with its fundamentals

Growth

What is NovoCure's growth rate over time

Valuation

What is NovoCure stock price valuation
P/E
N/A
P/B
4.86
P/S
2.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.63
NVCR's EPS is down by 25% since the previous quarter
The price to book (P/B) is 62% lower than the 5-year quarterly average of 12.9 but 8% higher than the last 4 quarters average of 4.5
The equity has declined by 9% year-on-year and by 2.9% since the previous quarter
NVCR's price to sales (P/S) is 75% lower than its 5-year quarterly average of 9.6
The company's revenue rose by 8% YoY and by 2.9% QoQ

Efficiency

How efficient is NovoCure business performance
NovoCure's ROIC has decreased by 44% YoY and by 31% from the previous quarter
The company's return on assets fell by 41% QoQ and by 24% YoY
NovoCure's return on equity has decreased by 30% QoQ and by 12% YoY
NVCR's return on sales is down by 16% since the previous quarter

Dividends

What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVCR.

Financial health

How did NovoCure financials performed over time
NovoCure's total assets is 72% more than its total liabilities
The company's current ratio has surged by 97% YoY
The company's quick ratio has surged by 91% YoY
NovoCure's debt is 29% less than its equity
NovoCure's debt has plunged by 66% YoY
NVCR's debt to equity has shrunk by 63% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.